Clinical Trial Update: Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma [Phase 2]

View source ↗

Summary

Phase II trial evaluating a triplet regimen of liposomal irinotecan, temozolomide, and fluzoparib for recurrent or metastatic Ewing sarcoma; the study is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma

Drugs mentioned

• Fluzoparib (fluzoparib)
• Onivyde (irinotecan hydrochloride liposome injection)
• Temodar (Temozolomide)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Ewing Sarcoma | Phase 2 | Status: RECRUITING